Frontiers in Innovative Pharmaceutical Modalities

Industry Overview

The innovative drug landscape has transitioned from traditional small molecules and monoclonal antibodies into an explosive paradigm of New Modalities: Antibody‑Drug Conjugates (ADCs), Bispecific/Multispecific Antibodies, Targeted Protein Degradation (PROTACs/Molecular Glues), Small Nucleic Acid Therapeutics, Cell & Gene Therapy (CGT), mRNA Cancer Vaccines, Peptide‑Drug Conjugates (PDCs), and AI‑Native Therapeutics represent the eight major frontier sectors. Oncology remains the primary battlefield, while autoimmune, metabolic, cardiovascular, and central nervous system (CNS) indications are expanding rapidly. Globally, numerous assets are advancing into pivotal Phase III trials, major out‑licensing deals, and regulatory approvals.

1. Antibody‑Drug Conjugates (ADCs)

Core Mechanism

Monoclonal antibodies selectively recognize tumor surface antigens, delivering cytotoxic payloads into tumor cells via linker cleavage to induce cell death. ADCs consist of three key components: antibody, linker, and payload.

Next‑Gen Iterations

Bispecific ADCs (bsADCs), dual‑payload ADCs, optimized cleavable/non‑cleavable linkers, novel payloads (e.g., TopoI inhibitors, immunomodulators), bystander effect modulation, and improved tumor microenvironment penetration—all aiming to overcome resistance, off‑target toxicity, and narrow therapeutic windows.

Representative Frontier Pipelines

• DS‑7300 (Ifinatamab deruxtecan, I‑DXd; Daiichi Sankyo / Merck): B7‑H3‑targeting ADC. Indications include extensive‑stage small cell lung cancer (SCLC), prostate cancer, and esophageal cancer. Granted FDA Breakthrough Therapy Designation with a target PDUFA date of October 10, 2026, positioning it as a potential first‑in‑class B7‑H3 ADC globally. Payload: DXd (Topoisomerase I inhibitor); Phase II data showed an ORR of approximately 52% in pretreated SCLC.
• Zocilurtatug pelitecan (ZOCI; Zai Lab): DLL3‑targeting ADC. Three registrational clinical trials are advancing for SCLC and neuroendocrine carcinoma, with key data readouts anticipated in 2026. Intracranial responses have been observed in patients with brain metastases.
• BL‑B01D1 (Izalnutatamab brecan; Baili‑Bio / BMS): EGFR×HER3 bispecific ADC (A global Phase III asset and one of the world's most advanced bispecific ADCs). Designed for EGFR‑resistant non‑small cell lung cancer (NSCLC) and various solid tumors, it overcomes single‑target resistance by simultaneously blocking EGFR and HER3 signaling pathways.
• HS‑20093 (Hansoh Pharma / GSK): B7‑H3 ADC. Advancing in global Phase III trials for SCLC, with GSK acquiring ex‑China rights to benchmark against DS‑7300.
• BCG039 & BCG026: BCG039 (Nectin‑4×TROP2 bsADC) & BCG026 (FAP×GPC1 ADC): In preclinical to Phase I stages targeting refractory solid tumors such as pancreatic cancer. By co‑targeting stromal and tumor cells, these assets aim to overcome dense stroma barriers.

2. Targeted Protein Degradation (TPD): PROTACs & Molecular Glues

Unlike traditional occupancy‑driven inhibitors, degradation agents act via an event‑driven mechanism, inducing ubiquitin‑proteasome system (UPS)‑mediated degradation of target proteins to address historically "undruggable" targets.

2.1 PROTACs (Proteolysis Targeting Chimeras)

Structure: Target protein ligand — Linker — E3 ubiquitin ligase ligand (Ternary complex).

Key Pipelines

• Vepdegestrant (ARV‑471; Arvinas / Pfizer): Targets ESR1‑mutated ER+/HER2‑ advanced breast cancer. It degrades mutant ERα to overcome endocrine therapy resistance. Currently in pivotal Phase III trials (VERITAC‑2), positioning it as a frontrunner to become the first FDA‑approved PROTAC.
• Bavdegalutamide (ARV‑110; Arvinas): Phase II clinical asset targeting AR degradation in prostate cancer.
• XYD224 / XYD270 (GIBH, CAS): Highly selective oral BRD9 PROTACs in preclinical development for synovial sarcoma and other malignant tumors.

2.2 Molecular Glue Degraders

Mechanism Advantages: Molecular glues do not require a target‑binding moiety; instead, they modify the E3 ligase surface conformation to recruit and degrade neo‑substrates. Featuring lower molecular weights and better Lipinski compliance, they exhibit superior druggability compared to PROTACs.

Key Pipelines

• Iberdomide (BMS): CRBN molecular glue for multiple myeloma, with BLA filing planned for 2026. Demonstrates a broader degradation spectrum and better safety profile than lenalidomide/pomalidomide.
• Emerging Targets: Multiple companies are pursuing novel molecular glue targets such as GSPT1 and ZCCHC10, mostly in preclinical to Phase I stages.

3. Bispecific & Multispecific Antibodies (BsAbs, TsAbs)

Single antibody molecules capable of simultaneously engaging two or more distinct epitopes. Primary mechanisms include T‑cell redirection (e.g., CD3 engagement), dual pathway blockade, and localized tumor microenvironment (TME) activation.

Frontier Hotspots & Key Pipelines

• Claudin 18.2 Targeted Therapies: Zolbetuximab (Vyloy) is an approved monoclonal antibody targeting Claudin 18.2; meanwhile, Claudin 18.2×CD3 bispecific antibodies (e.g., catumaxomab derivatives, IBI315) are advancing in Phase II/III trials for gastric and gastroesophageal junction cancers.
• PD‑1/PD‑L1 × Cytokine Immunocytokines: Fusions such as PD‑1/IL‑2 and PD‑1/IL‑12 eliminate systemic cytokine toxicity while achieving localized immune activation within the TME (e.g., ZL‑1222 in Phase I).
• IL‑13/IL‑31Rα Bispecific Antibody ZL‑1503 (Zai Lab): Under development for atopic dermatitis, with FIH data expected in 2H 2026, dual‑targeting inflammatory pathways in autoimmune diseases.

4. Small Nucleic Acid Therapeutics (siRNA / ASO / AOC)

Technical Breakthroughs: Expanding from rare diseases into large chronic disease markets. Major advances in extrahepatic delivery systems (e.g., AOCs, lipid modifications) are breaking historical limitations that restricted targeting to the liver.

Key Therapeutics & Pipelines

• Leqvio (Inclisiran; Novartis): A commercialized PCSK9‑targeting siRNA providing long‑acting LDL‑C reduction with bi‑annual dosing, opening a new era for chronic disease management via RNAi.
• Pelacarsen (Novartis ASO) & Olpasiran (Amgen siRNA): Both target Lp(a) with Phase III data readouts expected in 2026. As an independent cardiovascular risk factor, Lp(a) can be reduced by 80–95% via nucleic acid drugs, vastly outperforming small molecules.
• Delpacibart zotadirsen (AOC 1044 / Del‑zota; Avidity): Developed for Duchenne muscular dystrophy (DMD). As a landmark Antibody‑Oligonucleotide Conjugate (AOC) achieving extrahepatic delivery to skeletal muscle, global marketing applications are targeted for 2026.
• ARO‑SNCA (Arrowhead): An α‑synuclein‑targeting siRNA for Parkinson's disease; investigating subcutaneous/intrathecal administration to cross the blood‑brain barrier (BBB).
• ARO‑ALK7 (Arrowhead): An adipose‑targeted siRNA for weight management (Phase I); enables muscle‑sparing fat reduction, differing in mechanism from GLP‑1 receptor agonists.

5. Cell and Gene Therapy (CGT: CAR‑T, CAR‑NK, TCR‑T, Gene Editing)

• Autologous CAR‑T: Multiple products approved for hematologic malignancies; limitations include high personalized manufacturing costs, long turnaround times, and modest efficacy in solid tumors.
• Allogeneic (Off‑the‑shelf) CAR‑T: Utilizes CRISPR or base editing to knock out TCR and HLA genes to mitigate rejection; numerous Phase I/II pipelines aim to reduce costs and improve accessibility, though persistence in vivo remains a hurdle.
• TCR‑T: Recognizes HLA‑presented intracellular antigens (e.g., NY‑ESO‑1, MAGE), making it better suited for solid tumors. Requires strict control over off‑target toxicity against normal tissues.
• CAR‑NK: Derived from iPSCs or umbilical cord blood. Offers lower CRS risks and innate potential for off‑the‑shelf use, with iPSC‑derived CAR‑NK therapies representing a key industry focus.
• Gene Editing (Base & Prime Editing): Transitioning from Cas9 to base and prime editing to avoid DNA double‑strand breaks (DSBs) and chromosomal translocations; approved in sickle cell disease and β‑thalassemia, now expanding to metabolic diseases and oncology.

6. mRNA Therapeutics (Cancer Vaccines & Protein Replacement)

Milestone Progress: Moderna and Merck's individualized neoantigen mRNA cancer vaccine, Intamitinogene autoleucel (mRNA‑4157/V940), met its primary endpoint in a Phase III adjuvant trial for melanoma. Combined with pembrolizumab, it significantly reduced the risk of recurrence or distant metastasis, marking the world's first Phase III‑validated personalized mRNA cancer vaccine.

7. Peptides & Peptide‑Drug Conjugates (PDCs)

Advantages: Smaller molecular weight than antibodies allows deeper tumor tissue penetration, with higher target selectivity compared to traditional small molecules.

Key Pipelines

• PDCs: Peptide moieties target specific receptors coupled with cytotoxic payloads (e.g., approved Lutathera targeting somatostatin receptors). Numerous PDC assets are in Phase I/II clinical trials. Key challenges include short in vivo half‑lives and susceptibility to enzymatic degradation.
• Macrocycles: Target flat protein‑protein interaction (PPI) interfaces lacking conventional pockets. Example: CID‑078 (oral macrocycle targeting Cyclin A/B in Phase I for SCLC and TNBC).

8. AI‑Native Innovation Drugs

Industry Status: AI has expanded beyond early screening into full‑chain execution: target discovery, de novo molecule design, and formulation optimization. Globally over 170 AI‑empowered programs have entered clinical trials, with flagship assets reaching late‑stage development.

Key Pipelines

• Rentosertib (ISM001‑055; Insilico Medicine): A landmark asset featuring an AI‑discovered novel target (TNIK) and an AI‑generated novel molecule advancing in Phase III for idiopathic pulmonary fibrosis (IPF). Phase IIa data demonstrated significant improvement in FVC.
• GB‑0895 (Generate Biomedicines): An AI‑designed TSLP‑targeting monoclonal antibody for severe asthma, supporting semi‑annual dosing in global Phase III trials.
• MTS‑004 (METiS Therapeutics): An AI‑optimized orally disintegrating tablet for Pseudobulbar Affect (PBA), which has completed Phase III testing.

9. Other Emerging Directions (Oncolytic Viruses, RLT, iVAC)

• Radioligand Therapy (RLT): Targeted small molecules or peptides conjugated with radioisotopes (e.g., ¹⁷⁷Lu‑PSMA‑617). Commercial success in prostate cancer is driving expansion into small cell lung cancer and neuroendocrine tumors.
• In Situ Cancer Vaccines (iVAC): Intratumoral administration strategies (such as Peking University's iVAC approach) degrade PD‑L1 while presenting tumor antigens in situ, promoting tumor regression in animal models (preclinical stage).

Representative Late‑Stage Pipeline Summary